Asia Pacific Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

Description

List of Tables

The Asia Pacific gastrointestinal drugs market is projected to grow significantly, reaching an estimated US$ 22,377.77 million by 2031, up from US$ 12,145.18 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.9% from 2023 to 2031.

Executive Summary and Market Analysis

The Asia Pacific region encompasses several key countries, including China, Japan, India, Australia, South Korea, and others. The substantial populations in China and India, along with the increasing interest from pharmaceutical companies in this region, are driving market growth. Additionally, the rising incidence of gastrointestinal disorders, increased healthcare expenditure, and advancements in medical technology are further propelling the gastrointestinal drugs market.

Market Segmentation Analysis

The gastrointestinal drugs market in Asia Pacific can be segmented based on drug class, application, route of administration, and distribution channel:

1. Drug Class: The market is divided into several categories, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory ulcerative colitis, Crohn's disease, gastroenteritis, celiac disease, and others. The IBS segment held the largest share in 2023.

3. Route of Administration: The market is bifurcated into oral and parenteral routes. The oral administration segment dominated the market in 2023.

4. Distribution Channel: The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, with hospital pharmacies holding the largest market share in 2023.

Market Outlook

The prevalence of gastrointestinal diseases is on the rise globally, prompting increased funding for research aimed at developing new treatment methods. For example, the Yale School of Medicine receives over US$ 8 million annually from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to explore various gastrointestinal disorders, including inflammatory bowel disease (IBD) and liver diseases. Similarly, the UNC School of Medicine has over US$ 20 million in annual funding for research focused on gastrointestinal and liver diseases, emphasizing the importance of understanding these conditions and developing new therapies.

Recent advancements in clinical research, particularly the integration of artificial intelligence (AI), are transforming the landscape of gastrointestinal medicine. AI is increasingly utilized to analyze large datasets, leading to more personalized and effective treatment options. Machine learning algorithms can identify predictive markers for treatment responses, allowing for optimized therapeutic strategies tailored to individual patients.

AI is also enhancing diagnostic imaging in gastrointestinal medicine. By employing deep learning algorithms, researchers can analyze medical images, such as CT scans and endoscopic images, with high precision, facilitating early detection of gastrointestinal abnormalities. For instance, AI has shown promise in diagnosing colorectal polyps during colonoscopy, potentially reducing unnecessary surgical interventions. With funding from organizations like the Newcastle Permanent Charitable Foundation, researchers are exploring AI applications in developing new therapies for IBD and ulcerative colitis, focusing on the gut microbiome and intestinal stem cells.

The increasing investment in research for novel drug development and AI-based methodologies is expected to introduce innovative treatment solutions for gastrointestinal conditions, shaping future trends in the gastrointestinal drugs market.

Country Insights

The Asia Pacific gastrointestinal drugs market is characterized by significant contributions from various countries, with China leading the market in 2023. The growth in China can be attributed to its large population, the rising prevalence of gastrointestinal diseases, increasing pharmaceutical sales, and supportive regulatory frameworks.

China is actively enhancing its healthcare infrastructure and developing various medicinal products. A recent study indicated that the prevalence of irritable bowel syndrome (IBS) in China ranges from 3.2% to 17.7%, highlighting the substantial burden of gastrointestinal diseases in the country. In response, the Chinese government has implemented initiatives like the China Gastrointestinal Health Index (GHI) to monitor and control the incidence of these diseases, aiming to improve life expectancy and healthcare resource distribution.

The presence of both local and international pharmaceutical companies in China is fostering market growth. For instance, in September 2023, EA Pharma Co., Ltd. and TransThera Sciences, Inc. announced a strategic collaboration to develop advanced therapeutics targeting inflammatory diseases of the gastrointestinal system, showcasing the commitment to innovation in this sector.

Company Profiles

Key players in the Asia Pacific gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative solutions to consumers.

Product Code: TIPRE00016279

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Asia Pacific Gastrointestinal Drugs Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Cases of Gastrointestinal Diseases
- 4.1.2 Increasing Development of Biologics
4.2 Market Restraints
- 4.2.1 High Cost of Biologics
- 4.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
4.3 Market Opportunities
- 4.3.1 Strategic Initiatives by Companies
4.4 Future Trends
- 4.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
4.5 Impact of Drivers and Restraints:

5. Gastrointestinal Drugs Market - Asia Pacific Analysis

5.1 Asia Pacific Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Gastrointestinal Drugs Market Analysis - by Drug Class

6.1 Biologics
- 6.1.1 Overview
- 6.1.2 Biologics: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
6.2 Antidiarrheal and Laxatives
- 6.2.1 Overview
- 6.2.2 Antidiarrheal and Laxatives: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Acid Neutralizers
- 6.3.1 Overview
- 6.3.2 Acid Neutralizers: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Anti-inflammatory Drugs
- 6.4.1 Overview
- 6.4.2 Anti-inflammatory Drugs: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
6.5 Antiemetic and Antinauseants
- 6.5.1 Overview
- 6.5.2 Antiemetic and Antinauseants: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Gastrointestinal Drugs Market Analysis - by Application

7.1 Irritable Bowel Syndrome
- 7.1.1 Overview
- 7.1.2 Irritable Bowel Syndrome: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Inflammatory Ulcerative Colitis
- 7.2.1 Overview
- 7.2.2 Inflammatory Ulcerative Colitis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Crohn's Disease
- 7.3.1 Overview
- 7.3.2 Crohn's Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Gastroenteritis
- 7.4.1 Overview
- 7.4.2 Gastroenteritis: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Celiac Disease
- 7.5.1 Overview
- 7.5.2 Celiac Disease: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Gastrointestinal Drugs Market Analysis - by Route of Administration

8.1 Oral
- 8.1.1 Overview
- 8.1.2 Oral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Parenteral
- 8.2.1 Overview
- 8.2.2 Parenteral: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Gastrointestinal Drugs Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Online Pharmacies
- 9.3.1 Overview
- 9.3.2 Online Pharmacies: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Gastrointestinal Drugs Market - Country Analysis

10.1 Asia Pacific
- 10.1.1 Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast Analysis - by Country
  - 10.1.1.1 China: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.1.1 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 10.1.1.1.2 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
    - 10.1.1.1.3 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 10.1.1.1.4 China: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 10.1.1.2 Japan: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.2.1 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 10.1.1.2.2 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
    - 10.1.1.2.3 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 10.1.1.2.4 Japan: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 10.1.1.3 India: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.3.1 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 10.1.1.3.2 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
    - 10.1.1.3.3 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 10.1.1.3.4 India: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 10.1.1.4 Australia: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.4.1 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 10.1.1.4.2 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
    - 10.1.1.4.3 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 10.1.1.4.4 Australia: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 10.1.1.5 South Korea: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.5.1 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 10.1.1.5.2 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
    - 10.1.1.5.3 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 10.1.1.5.4 South Korea: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel
  - 10.1.1.6 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.6.1 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Drug Class
    - 10.1.1.6.2 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Application
    - 10.1.1.6.3 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Route Of Administration
    - 10.1.1.6.4 Rest of APAC: Asia Pacific Gastrointestinal Drugs Market Breakdown, by Distribution Channel

11. Industry Landscape

11.1 Overview
11.2 Growth Strategies in Asia Pacific Gastrointestinal Drugs Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Sanofi SA
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 GSK Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Johnson & Johnson
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Bausch Health Companies Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 AstraZeneca Plc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Takeda Pharmaceutical Co Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 AbbVie Inc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Bayer AG
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Celltrion Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Pfizer Inc
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms